Search ICCC
IMMUCELL CORP /DE/
Nasdaq · CIK 811641
Last close9.75
Daily change+0.15 (1.56%)
10 Years gain+27.28%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
ICCC · STANDARD
SIC 2835 · In Vitro & In Vivo Diagnostic Substances · Fiscal year end 1231
Fundamental
56.0Momentum
100.0Acceleration
100.0Confidence
83.0Annual Revenue15
Quarterly Revenue48
Annual CFO17
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth13.4 / 25
Quality15.6 / 25
Capital Efficiency10.9 / 20
Balance Sheet13.3 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Gross margin expansionGross margin improved by 10.0515 percentage points.
Operating leverageOperating margin improved by 19.5033 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Key Metrics
Revenue Growth TTM10.02%OK
Revenue CAGR 3Y14.19%OK
Gross Margin41.62%OK
Operating Margin15.24%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC13.52%OK
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y2.32%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $27.64M | $11.45M | $1.65M | $2.48M | $1.22M | 41.4% | 5.97% | 4.43% | 3.91% | 9.03M |
| 2025 FY Dec 31, 2024 | $26.49M | $7.94M | -$1.64M | $357,903.00 | -$107,822.00 | 29.97% | -6.19% | -0.41% | n/a | 8.17M |
| 2024 FY Dec 31, 2023 | n/a | $3.87M | -$5.75M | -$4.67M | -$6.57M | n/a | n/a | n/a | n/a | 7.75M |
| 2023 FY Dec 31, 2023 | $17.47M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| 2024 FY Dec 31, 2022 | n/a | $7.65M | -$2.30M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $29.49M | sum latest 4 fiscal quarters Revenue | OK | 0001437749-26-027668, 0001437749-25-034817 |
| Revenue Growth TTM | 10.02% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001437749-26-027668, 0001437749-25-034817 |
| Revenue CAGR 3Y | 14.19% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001437749-26-010339 |
| Revenue CAGR 5Y | 12.5% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001437749-26-010339 |
| Gross Profit CAGR 3Y | n/a | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | INSUFFICIENT_HISTORY | 0001437749-26-010339 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001437749-26-027668, 0001437749-25-034817 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 41.62% | Gross Profit / Revenue | OK | 0001437749-26-027668, 0001437749-25-034817 |
| Operating Margin | 15.24% | Operating Income / Revenue | OK | 0001437749-26-027668, 0001437749-25-034817 |
| ROIC | 13.52% | NOPAT / Average Invested Capital | OK | 0001437749-26-027668, 0001437749-25-034817 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001437749-26-027668 |
| Current Ratio | 4.75x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 1.07x | (Cash + Short-term Investments) / Total Debt | OK | 0001437749-26-027668 |
| Revenue per Diluted Share | $3.21 | Revenue / Diluted Shares | OK | 0001437749-26-027668, 0001437749-25-034817 |